Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,446 INR | -1.26% | -6.09% | -2.31% |
05-02 | Transcript : Neogen Chemicals Limited, Q4 2024 Earnings Call, May 02, 2024 | |
04-30 | Neogen Chemicals Limited Recommends Final Dividend for the Financial Year 2023-2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 78.58 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.31% | 457M | C | ||
+1.61% | 49.2B | A- | ||
+16.33% | 41.24B | B+ | ||
+18.68% | 25.89B | A- | ||
+12.78% | 19.81B | C+ | ||
+0.85% | 17.48B | B+ | ||
-21.87% | 15.86B | A- | ||
+2.32% | 15.35B | B+ | ||
-10.29% | 15.23B | C+ | ||
-22.30% | 13.36B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NEOGEN Stock
- Ratings Neogen Chemicals Limited